Co-Authors
This is a "connection" page, showing publications co-authored by NAOTO T UENO and GILDY BABIERA.
Connection Strength
1.341
-
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213.
Score: 0.169
-
International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018; 9(8):1437-1447.
Score: 0.165
-
Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. Breast Cancer Res Treat. 2018 Jun; 169(3):615-623.
Score: 0.163
-
Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast?Cancer. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1218-25.
Score: 0.143
-
Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):417.
Score: 0.136
-
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):407-16.
Score: 0.135
-
Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J Clin Oncol. 2014 Jul 01; 32(19):2018-24.
Score: 0.126
-
Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer. 2014 May 01; 120(9):1319-28.
Score: 0.123
-
Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast?Cancer. Clin Breast Cancer. 2018 02; 18(1):e73-e77.
Score: 0.039
-
4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells. Cancer Immunol Res. 2017 06; 5(6):439-445.
Score: 0.039
-
Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer. 2017 Jul 15; 123(14):2618-2625.
Score: 0.038
-
Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer. 2015 Dec 15; 121(24):4324-32.
Score: 0.034
-
Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. Springerplus. 2014; 3:166.
Score: 0.031